mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy
Dendritic cells (DCs) are attractive antigen-presenting cells to be targeted for vaccinations. However, the systemic delivery of mRNA to DCs is hampered by technical challenges. We recently reported that it is possible to regulate the size of RNA-loaded lipid nanoparticles (LNPs) to over 200 nm with...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/8/1572 |
| _version_ | 1797442770658394112 |
|---|---|
| author | Kosuke Sasaki Yusuke Sato Kento Okuda Kazuki Iwakawa Hideyoshi Harashima |
| author_facet | Kosuke Sasaki Yusuke Sato Kento Okuda Kazuki Iwakawa Hideyoshi Harashima |
| author_sort | Kosuke Sasaki |
| collection | DOAJ |
| description | Dendritic cells (DCs) are attractive antigen-presenting cells to be targeted for vaccinations. However, the systemic delivery of mRNA to DCs is hampered by technical challenges. We recently reported that it is possible to regulate the size of RNA-loaded lipid nanoparticles (LNPs) to over 200 nm with the addition of salt during their formation when a microfluidic device is used and that larger LNPs delivered RNA more efficiently and in greater numbers to splenic DCs compared to the smaller counterparts. In this study, we report on the in vivo optimization of mRNA-loaded LNPs for use in vaccines. The screening included a wide range of methods for controlling particle size in addition to the selection of an appropriate lipid type and its composition. The results showed a clear correlation between particle size, uptake and gene expression activity in splenic DCs and indicated that a size range from 200 to 500 nm is appropriate for use in targeting splenic DCs. It was also found that it was difficult to predict the transgene expression activity and the potency of mRNA vaccines in splenic DCs using the whole spleen. A-11-LNP, which was found to be the optimal formulation, induced better transgene expression activity and maturation in DCs and induced clear therapeutic antitumor effects in an E.G7-OVA tumor model compared to two clinically relevant LNP formulations. |
| first_indexed | 2024-03-09T12:46:49Z |
| format | Article |
| id | doaj.art-639caf0a84cc47d98a3c89526af2dbeb |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T12:46:49Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-639caf0a84cc47d98a3c89526af2dbeb2023-11-30T22:11:05ZengMDPI AGPharmaceutics1999-49232022-07-01148157210.3390/pharmaceutics14081572mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer ImmunotherapyKosuke Sasaki0Yusuke Sato1Kento Okuda2Kazuki Iwakawa3Hideyoshi Harashima4Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, JapanLaboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, JapanLaboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, JapanLaboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, JapanLaboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, JapanDendritic cells (DCs) are attractive antigen-presenting cells to be targeted for vaccinations. However, the systemic delivery of mRNA to DCs is hampered by technical challenges. We recently reported that it is possible to regulate the size of RNA-loaded lipid nanoparticles (LNPs) to over 200 nm with the addition of salt during their formation when a microfluidic device is used and that larger LNPs delivered RNA more efficiently and in greater numbers to splenic DCs compared to the smaller counterparts. In this study, we report on the in vivo optimization of mRNA-loaded LNPs for use in vaccines. The screening included a wide range of methods for controlling particle size in addition to the selection of an appropriate lipid type and its composition. The results showed a clear correlation between particle size, uptake and gene expression activity in splenic DCs and indicated that a size range from 200 to 500 nm is appropriate for use in targeting splenic DCs. It was also found that it was difficult to predict the transgene expression activity and the potency of mRNA vaccines in splenic DCs using the whole spleen. A-11-LNP, which was found to be the optimal formulation, induced better transgene expression activity and maturation in DCs and induced clear therapeutic antitumor effects in an E.G7-OVA tumor model compared to two clinically relevant LNP formulations.https://www.mdpi.com/1999-4923/14/8/1572lipid nanoparticlesparticle sizedendritic cellsmRNAdeliverycancer immunotherapy |
| spellingShingle | Kosuke Sasaki Yusuke Sato Kento Okuda Kazuki Iwakawa Hideyoshi Harashima mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy Pharmaceutics lipid nanoparticles particle size dendritic cells mRNA delivery cancer immunotherapy |
| title | mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy |
| title_full | mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy |
| title_fullStr | mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy |
| title_full_unstemmed | mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy |
| title_short | mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy |
| title_sort | mrna loaded lipid nanoparticles targeting dendritic cells for cancer immunotherapy |
| topic | lipid nanoparticles particle size dendritic cells mRNA delivery cancer immunotherapy |
| url | https://www.mdpi.com/1999-4923/14/8/1572 |
| work_keys_str_mv | AT kosukesasaki mrnaloadedlipidnanoparticlestargetingdendriticcellsforcancerimmunotherapy AT yusukesato mrnaloadedlipidnanoparticlestargetingdendriticcellsforcancerimmunotherapy AT kentookuda mrnaloadedlipidnanoparticlestargetingdendriticcellsforcancerimmunotherapy AT kazukiiwakawa mrnaloadedlipidnanoparticlestargetingdendriticcellsforcancerimmunotherapy AT hideyoshiharashima mrnaloadedlipidnanoparticlestargetingdendriticcellsforcancerimmunotherapy |